Compare VENUS REMEDIES with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES STRIDES PHARMA SCIENCE VENUS REMEDIES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -1.0 15.1 - View Chart
P/BV x 0.1 0.9 8.2% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 VENUS REMEDIES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
VENUS REMEDIES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1261,147 11.0%   
Low Rs61642 9.5%   
Sales per share (Unadj.) Rs301.8317.2 95.1%  
Earnings per share (Unadj.) Rs-24.97.8 -317.0%  
Cash flow per share (Unadj.) Rs2.525.1 10.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs293.3274.3 106.9%  
Shares outstanding (eoy) m12.3489.50 13.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 11.0%   
Avg P/E ratio x-3.8114.0 -3.3%  
P/CF ratio (eoy) x36.735.7 102.9%  
Price / Book Value ratio x0.33.3 9.8%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m1,15480,058 1.4%   
No. of employees `0000.92.5 36.9%   
Total wages/salary Rs m3934,341 9.1%   
Avg. sales/employee Rs Th4,026.111,325.8 35.5%   
Avg. wages/employee Rs Th425.01,731.4 24.5%   
Avg. net profit/employee Rs Th-331.8280.1 -118.5%   
INCOME DATA
Net Sales Rs m3,72428,394 13.1%  
Other income Rs m23941 2.4%   
Total revenues Rs m3,74729,334 12.8%   
Gross profit Rs m3953,965 10.0%  
Depreciation Rs m3381,540 22.0%   
Interest Rs m3541,962 18.1%   
Profit before tax Rs m-2751,403 -19.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m3297 32.5%   
Profit after tax Rs m-307702 -43.7%  
Gross profit margin %10.614.0 75.9%  
Effective tax rate %-11.56.9 -165.5%   
Net profit margin %-8.22.5 -333.3%  
BALANCE SHEET DATA
Current assets Rs m2,63824,836 10.6%   
Current liabilities Rs m2,30518,993 12.1%   
Net working cap to sales %8.920.6 43.5%  
Current ratio x1.11.3 87.5%  
Inventory Days Days13571 190.8%  
Debtors Days Days46113 40.9%  
Net fixed assets Rs m4,87134,289 14.2%   
Share capital Rs m123895 13.8%   
"Free" reserves Rs m3,49623,651 14.8%   
Net worth Rs m3,61924,546 14.7%   
Long term debt Rs m1,37415,513 8.9%   
Total assets Rs m7,50965,437 11.5%  
Interest coverage x0.21.7 13.0%   
Debt to equity ratio x0.40.6 60.1%  
Sales to assets ratio x0.50.4 114.3%   
Return on assets %0.64.1 15.5%  
Return on equity %-8.52.9 -296.5%  
Return on capital %1.66.9 22.9%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m015,697 0.0%   
Fx outflow Rs m517735 70.2%   
Net fx Rs m-51714,962 -3.5%   
CASH FLOW
From Operations Rs m5141,871 27.5%  
From Investments Rs m-1235,826 -2.1%  
From Financial Activity Rs m-387-10,157 3.8%  
Net Cashflow Rs m4-2,615 -0.2%  

Share Holding

Indian Promoters % 32.9 27.7 118.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 37.8 0.5%  
FIIs % 0.6 8.6 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 25.9 256.4%  
Shareholders   20,121 56,241 35.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 17, 2019 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - NATCO PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS